Epigenetic potentiation of somatostatin-2 by guadecitabine in neuroendocrine neoplasias as a novel method to allow delivery of peptide receptor radiotherapy.
Quick Facts
What This Study Found
Guadecitabine treatment resulted in a 150% increase in SSTR2 uptake in BON-1 models.
Key Numbers
How They Did This
The study involved in vitro and in vivo experiments using neuroendocrine neoplasia models, methylation profiling of clinical samples, and safety assessments for combined treatment.
Why This Research Matters
Enhancing SSTR2 expression could expand treatment options for patients with neuroendocrine neoplasias who currently lack effective therapies. This research opens the door for improved outcomes in peptide receptor radionuclide therapy.
What This Study Doesn't Tell Us
The study primarily focused on specific cell lines and may not fully represent all neuroendocrine neoplasias in patients.
Trust & Context
- Original Title:
- Epigenetic potentiation of somatostatin-2 by guadecitabine in neuroendocrine neoplasias as a novel method to allow delivery of peptide receptor radiotherapy.
- Published In:
- European journal of cancer (Oxford, England : 1990), 176, 110-120 (2022)
- Authors:
- Evans, Joanne S, Beaumont, Jamie, Braga, Marta, Masrour, Nahal, Mauri, Francesco, Beckley, Alice, Butt, Shamus, Karali, Christina S, Cawthorne, Chris, Archibald, Stephen, Aboagye, Eric O, Sharma, Rohini
- Database ID:
- RPEP-06114
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-06114APA
Evans, Joanne S; Beaumont, Jamie; Braga, Marta; Masrour, Nahal; Mauri, Francesco; Beckley, Alice; Butt, Shamus; Karali, Christina S; Cawthorne, Chris; Archibald, Stephen; Aboagye, Eric O; Sharma, Rohini. (2022). Epigenetic potentiation of somatostatin-2 by guadecitabine in neuroendocrine neoplasias as a novel method to allow delivery of peptide receptor radiotherapy.. European journal of cancer (Oxford, England : 1990), 176, 110-120. https://doi.org/10.1016/j.ejca.2022.09.009
MLA
Evans, Joanne S, et al. "Epigenetic potentiation of somatostatin-2 by guadecitabine in neuroendocrine neoplasias as a novel method to allow delivery of peptide receptor radiotherapy.." European journal of cancer (Oxford, 2022. https://doi.org/10.1016/j.ejca.2022.09.009
RethinkPeptides
RethinkPeptides Research Database. "Epigenetic potentiation of somatostatin-2 by guadecitabine i..." RPEP-06114. Retrieved from https://rethinkpeptides.com/research/evans-2022-epigenetic-potentiation-of-somatostatin2
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.